

# In vitro determination of the antibiotic susceptibility of biofilm-forming *Pseudomonas aeruginosa* and *Staphylococcus aureus*: possible role of proteolytic activity and membrane lipopolysaccharide

Majed M Masadeh<sup>1</sup>  
Nizar M Mhaidat<sup>2</sup>  
Karem H Alzoubi<sup>2</sup>  
Emad I Hussein<sup>3</sup>  
Esra'a I Al-Trad<sup>4</sup>

<sup>1</sup>Department of Pharmaceutical Technology, <sup>2</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan; <sup>3</sup>Department of Biological Sciences, Yarmouk University, Irbid, Jordan; <sup>4</sup>Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan

**Abstract:** We carried out a comprehensive overview of inhibitory effects of selected antibiotics on planktonic and biofilm cells of *Staphylococcus aureus* (ATCC 29213) and *Pseudomonas aeruginosa* (ATCC 27853) strains. The possible involvement of protease activity and the lipopolysaccharide (LPS) profile of *P. aeruginosa* were also analyzed. Biofilm cells of both strains were more resistant to antibiotics than their planktonic counterparts. Protease activity was increased in both strains in the biofilm forms. Challenge with sublethal doses of antibiotics also increased proteolytic activity of biofilm cells. Additionally, the LPS profile of *P. aeruginosa* showed pattern alterations of the biofilm that can contribute to biofilm resistance and survival. These observations provide evidence for the involvement of bacterial proteolytic activity and LPS profile in the resistance of biofilm bacteria to antibiotics compared to their planktonic counterparts.

**Keywords:** biofilm, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, proteolytic activity, lipopolysaccharide

Many pathogenic and commensal bacteria are capable of transitioning between lifestyles in the environment and the human host.<sup>1</sup> These bacteria must be able to adapt to sudden shifts in availability of nutrients and to primary and secondary host immune defenses.<sup>2</sup> One particularly important and clinically relevant example of bacterial adaptation is the ability to grow as biofilms.<sup>3-5</sup>

Biofilms, a surface-associated bacterial community, are complex and ordered bacterial societies that are capable of growing in connection with different biological or inert surfaces.<sup>1</sup> The major clinical consequence of different disease-causing bacteria correlates with the problems of therapeutic killing of attached cells.<sup>6</sup> Biofilms are commonly associated with many health problems, such as endocarditis, otitis media, periodontitis, prostatitis, and urinary tract infections.<sup>7-10</sup> Several bacteria, such as *Escherichia coli*, *Staphylococcus aureus*, *Haemophilus influenza*, and *Pseudomonas aeruginosa*, can form biofilms in the body tissues, leading to different infections.<sup>10-12</sup> It has been estimated that biofilms account for two-thirds of the bacterial infections that physicians encounter, particularly in immunocompromised patients.<sup>13</sup>

Antibiotics have been used to treat patients with infectious diseases. They target important bacterial structures and cellular pathways, such as the cell wall, DNA, RNA,

Correspondence: Majed M Masadeh  
Department of Pharmaceutical  
Technology, Faculty of Pharmacy, Jordan  
University of Science and Technology,  
Irbid 221 10, Jordan  
Tel +962 2 720 1000  
Fax +962 2 720 1075  
Email mmmasadeh@just.edu.jo

protein synthesis machinery, and bacterial metabolism.<sup>14</sup> However, uncontrolled or long-term use of antibiotics results in the adaptation and development of resistance leading to treatment failure, prolonged or additional hospitalization, increased costs of care, and increased mortality.<sup>11,15</sup> The mechanism of resistance of microbial biofilms to antibiotics is not clear. However, it seems to be multifactorial and may vary from one organism to another.<sup>16</sup> In this study we investigated the possible involvement of proteolytic activity and lipopolysaccharides (LPSs) in increased resistance to antibiotics during the biofilm state.

## Materials and methods

### Bacterial strains and culture

*Pseudomonas aeruginosa* (ATCC 27853) and *S. aureus* (ATCC 29213) strains were obtained from the American type culture collection and cultivated on Mueller Hinton agar (Becton Dickinson and Company, Cockeysville, MD, USA) for 24 hours at 37°C under standardized aseptic conditions.

### Antimicrobial agents

The following antimicrobial agents were used for susceptibility testing against *S. aureus*: cefaclor (cephalosporins) at a concentration of (32 µg/mL), amoxicillin (aminoglycosides; 32 µg/mL), cotrimoxazole (sulfonamides/folic acid antagonists; 32 µg/mL), and ciprofloxacin (fluoroquinolones; 0.125 µg/mL). We used amikacin (aminoglycosides, 0.25 µg/mL) and cotrimoxazole (32 µg/mL), ciprofloxacin (0.0625 µg/mL), and ceftazidime (32 µg/mL) (cephalosporins) for susceptibility testing against *P. aeruginosa*. All antibiotics were used as raw material, and purchased from Sigma-Aldrich, MI, USA.

### Bacterial culture

*Staphylococcus aureus* and *P. aeruginosa* biofilms were developed as previously described<sup>17</sup> under standardized aseptic conditions. Briefly, 100 µL of bacterial suspension from each strain was cultivated in polypropylene tubes containing 2 mL of trypticase soy broth (TSB) supplemented with 1% glucose (Becton Dickinson and Company, Cockeysville, MD, USA) for 48 hours at 37°C. Culture media was refreshed after 24 hours of incubation. After 48 hours of incubation, biofilm cells were harvested by discarding the culture media and washing the tubes three times with phosphate buffer saline (PBS; pH 7.2) to remove nonadherent bacteria; the adhered cells were then harvested by vortex and centrifugation. The pellet was suspended in PBS (pH 7.2) to achieve the desired turbidity (comparable to a McFarland turbidity standard of 0.5). Screening for biofilm formation was achieved as previously described.<sup>18</sup> Briefly, after being emptied from their content,

culture tubes were stained with trypan blue or safranin. Biofilms were judged by the appearance of a visible film lining the walls of the tube. Observations were carried out by three independent observers. Biofilms were scored as absent (score 0), weak (score 1), moderate (score 2), or strong (score 3). Average scores were used.

### Determination of minimum inhibitory concentrations (MICs) of antibiotics for planktonic and biofilm cells

The MIC values of both *S. aureus* and *P. aeruginosa* planktonic and biofilm cells were tested against selected antibiotics. MICs were determined by using the broth macrodilution method.<sup>19</sup> Briefly, 100 µL of adjusted bacterial suspensions equivalent to a 0.5 McFarland standard were added to a twofold serial dilution of selected antibiotics diluted in Mueller Hinton broth. The results were observed after 24 hours of incubation at 37°C. The lowest concentration of antibiotic needed to inhibit microbial growth compared to the control culture was defined as the MIC. Tests were performed in triplicate for each antibiotic.

### Influence of sub-MICs of selected antibiotics on biofilm cells

To determine the effects of sub-MICs of antibiotics on *S. aureus* and *P. aeruginosa* biofilms, 100 µL of a bacterial biofilm suspension was added to TSB (supplemented with 1% glucose) containing sub-MICs of each antibiotic (for *S. aureus*: ciprofloxacin 32 µg/ml, cotrimoxazole 32 µg/ml, cefaclor 32 µg/ml, amoxicillin 32 µg/ml; and for *P. aeruginosa*: ciprofloxacin 8 µg/ml, amikacin 0.003 µg/ml, ceftazidime 32 µg/ml), and the suspension + antibiotic was then incubated at 37°C for 24 hours. After incubation, the antibiotics were removed by washing the tubes three times, and the cells were pelleted for further investigation.

### Proteolytic activity assay

Total protease activity of *S. aureus* and *P. aeruginosa* in planktonic and biofilm cells was determined by the azocasein assay.<sup>20</sup> Briefly, media from each bacterial strain (30 mL) was added to 50 mL azocasein substrate (2% azocasein (Sigma-Aldrich, MI, USA) in 10 mM Tris HCl, 8 mM CaCl<sub>2</sub>, pH 7.4). The reaction mixture was incubated for 20 hours. Thereafter, 240 mL 10% trichloroacetic acid was added, and the samples were mixed and allowed to stand for 15 minutes to ensure complete precipitation of undigested material. Tubes were centrifuged at 10,600 xg for 10 minutes, and 240 mL of the

supernatant was transferred to tubes containing 280 mL 1.0 M NaOH. The absorbance at 440 nm was determined against a blank tube. One unit of enzyme activity corresponds to the absorbance at maximal digestion of 1 mg azocasein/hour.<sup>21</sup> The protease activity was expressed as units/10<sup>6</sup> bacteria/hour.<sup>20</sup>

## LPS extraction and analysis

We followed the LPS extraction kit guidelines (Intron Biotechnology, Kyungki-Do, Republic of Korea) to extract LPSs from *P. aeruginosa* planktonic and biofilm cells and biofilms induced with sub-MICs of antibiotics. The LPS profile was then determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) comprising a 4% stacking gel and a 12% separation gel.<sup>22</sup> The LPS gel was then fixed and stained according to the method of Tsai and Frasch.<sup>23</sup>

## Statistical analysis

Analysis was performed using GraphPad Prism software (version 4.0; GraphPad Software, Inc, La Jolla, CA). One-way analyses of variance followed by Dunnett's post hoc test were used to determine any statistically significant difference. A *P*-value < 0.05 was considered significant.

## Results

The MIC values of selected antibiotics against *S. aureus* and *P. aeruginosa* biofilm and planktonic cells were determined (Tables S1 and S2). The MIC values of biofilms were generally higher than their planktonic counterparts.

We determined protease activity of *S. aureus* and *P. aeruginosa* in order to evaluate the possible involvement of proteolytic activity in the resistance of the biofilm form of bacteria (Tables 1 and 2). Results demonstrated that control biofilm had significantly higher proteolytic activity than its

**Table 2** Protease activity of *Pseudomonas aeruginosa* cells

Samples	Proteolytic activity (units/10 <sup>6</sup> bacterial/hour)
Planktonic	2.89 ± 0.47
Biofilm	4.44 ± 0.38*
Biofilm treated with (1/8) MIC of ciprofloxacin	5.33 ± 0.46*
Biofilm treated with (1/8) MIC amikacin	5.78 ± 0.61*
Biofilm treated with (1/8) MIC ceftazidime	5.10 ± 0.44*

**Notes:** n = 4 experiments. \*indicates significant difference from the planktonic group at *P* < 0.05.

**Abbreviation:** MIC, minimum inhibitory concentration.

planktonic counterpart. When biofilms cells were exposed to sub-MICs of selected antibiotics, most showed a slight but not significant increase in their proteolytic activity.


LPSs of the *P. aeruginosa* cell membrane also have an essential barrier function and directly affect bacterial susceptibility for antibiotics.<sup>24</sup> We therefore analyzed the LPS profile by SDS-PAGE and silver stain. LPSs displayed a ladder-like pattern of bands with the slower migrating band of the LPS extract in the O-antigen region and the faster band in the lipid A region (Figure 1). In comparison to planktonic cells, biofilm-forming cells showed a different LPS profile; the faster migrating band (lipid A) had an increased staining intensity and a slightly decreased number of bands in the O-antigen region. In the presence of (1/8) MIC of ceftazidime, the number of bands in the O-antigen region increased and the faster migrating band (lipid A) decreased to being barely observable when compared with the control biofilm. For (1/4) MIC of ciprofloxacin and (1/8) MIC of amikacin, the number of bands in the O-antigen region decreased slightly and lipid A intensity increased.

**Table 1** Protease activity of *Staphylococcus aureus* cells

Samples	Proteolytic activity (units/10 <sup>6</sup> bacterial/hour)
Planktonic	2.00 ± 0.33
Biofilm	3.34 ± 0.55*
Biofilm treated with (1/4) MIC of ciprofloxacin	2.44 ± 0.40
Biofilm treated with (1/32) MIC of cefaclor	2.88 ± 0.43
Biofilm treated with (1/8) MIC of cotrimoxazole	3.56 ± 0.65*
Biofilm treated with (1/16) MIC of amoxicillin	6.44 ± 0.57*

**Notes:** n = 4 experiments. \*indicates significant difference from the planktonic group at *P* < 0.05.

**Abbreviation:** MIC, minimum inhibitory concentration.



**Figure 1** Electrophoretic profile of LPS of *Pseudomonas aeruginosa*.

**Notes:** Lane 1, LPS extracted from biofilm cells; lane 2, LPS extracted from planktonic cells; lane 3, LPS extracted from biofilm cells treated with (1/8) MIC of ceftazidime; lane 4, LPS extracted from biofilm cells treated with (1/4) MIC of ciprofloxacin; lane 5, LPS extracted from biofilm cells treated with (1/8) MIC of amikacin.

**Abbreviations:** LPS, lipopolysaccharide; MIC, minimum inhibitory concentration.

## Discussion

Biofilm forms of bacteria are responsible for a variety of life-threatening infections. They have the ability to resist attack by host defenses and show resistance to most antibiotics.<sup>25,26</sup> A wide range of pathogens, such as *P. aeruginosa* and *S. aureus*, are capable of forming biofilms. Both bacterial types are medically significant microbes and can cause implant and prosthetic device infections. Thus, assessment of possible mechanisms for antibiotic resistance in their biofilm form is critical.

Results of this study showed that proteolytic activity increases when bacteria switch from a planktonic to biofilm phenotype. This indicates that biofilms are more virulent and have a greater ability to cause tissue destruction, which correlates with the conclusions of previous studies.<sup>27–29</sup> Additionally, the proteolytic potential slightly increased when biofilms were exposed to sublethal concentrations of selected antibiotics. This possibly explains results of clinical studies that show increased severity of disease when subtherapeutic doses or inadequate duration of antibiotics are used.<sup>30–33</sup>

LPSs are a major constituent of the *P. aeruginosa* membrane, and changes observed in membrane structure may result in changes to the antibiotic permeability barrier.<sup>34,35</sup> For example, the presence of full-length O-antigen renders the LPS smooth, whereas absence or reduction of O-antigen makes the LPS rough. This represents a bacterial shift from an acute to chronic lifestyle, leading to increased persistence of bacteria and a consequent high relapse of disease.<sup>36</sup> Results of our study showed decreased O-antigen and increased lipid A in biofilm-forming cells compared to planktonic cells, indicating a phenotypic switch in the LPSs from a smooth form to a rough form.<sup>37</sup>

Apart from an LPS role in resistance, LPSs are generally considered endotoxins.<sup>38</sup> Accordingly, the increased virulence of *P. aeruginosa* biofilms compared to the planktonic form could be related to an increase in lipid A. In the LPS pattern of *P. aeruginosa*-treated biofilms, lipid A expression in biofilms exposed to amikacin and ciprofloxacin was up-regulated compared to untreated biofilms. These changes in LPS expression indicate that antibiotic-exposed biofilms had more virulence potential than untreated biofilms. Further studies are required to elucidate the mechanisms by which these antibiotics induce changes in LPSs.

In this study we investigated the effect of certain antibiotics on proteolytic activity of *P. aeruginosa* and *S. aureus* and/or membrane LPSs of *P. aeruginosa*. We chose antibiotics that are most commonly used for the treatment

of infections by these two bacterial strains. Future work could cover other important antibiotics and also commonly used antibiotics, such as vancomycin and aztreonam. Studies should also address the possibility of membrane protein involvement in increased virulence of biofilms, especially when challenged with sublethal concentrations of antibiotics.

Collectively, the antibiotic susceptibility results presented in this study showed that biofilms are more tolerant to antimicrobial agents than planktonic forms. Biofilms (control and treated strains) revealed changes in proteolytic activity and LPS patterns that may result in antibiotic resistance. A decrease in O-antigen bands of LPSs could be a mechanism that helps biofilms evade the immune system, while increased lipid A contents may indicate an increase in biofilm endotoxicity. These LPS changes along with increased protease activity indicate that biofilms are more virulent than their planktonic counterparts.

## Acknowledgment

This project was supported by a grant (No 37/2010) from the Deanship of Research at the Jordan University of Science and Technology.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Johnjuly W, Fuge LH, Kad M, Post C. Introduction to biofilms in family medicine. *South Med J*. 2012;105(1):24–29.
2. Wolcott R, Dowd S. The role of biofilms: are we hitting the right target? *Plast Reconstr Surg*. 2011;127(Suppl 1):28S–35S.
3. Brooks JL, Jefferson KK. Staphylococcal biofilms: quest for the magic bullet. *Adv Appl Microbiol*. 2012;81:63–87.
4. Aparna MS, Yadav S. Biofilms: microbes and disease. *Braz J Infect Dis*. 2008;12(6):526–530.
5. Lynch AS, Robertson GT. Bacterial and fungal biofilm infections. *Annu Rev Med*. 2008;59:415–428.
6. Wang X, Wood TK. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. *Appl Environ Microbiol*. 2011;77(16):5577–5583.
7. Wilson SK, Costerton JW. Biofilm and penile prosthesis infections in the era of coated implants: a review. *J Sex Med*. 2012;9(1):44–53.
8. Huang R, Li M, Gregory RL. Bacterial interactions in dental biofilm. *Virulence*. 2011;2(5):435–444.
9. Vlassova N, Han A, Zenilman JM, James G, Lazarus GS. New horizons for cutaneous microbiology: the role of biofilms in dermatological disease. *Br J Dermatol*. 2011;165(4):751–759.
10. Davey ME, O'Toole GA. Microbial biofilms: from ecology to molecular genetics. *Microbiol Mol Biol Rev*. 2000;64(4):847–867.
11. Kyd JM, McGrath J, Krishnamurthy A. Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. *Curr Drug Targets*. 2011;12(4):521–530.
12. Jensen PO, Givskov M, Bjarnsholt T, Moser C. The immune system vs *Pseudomonas aeruginosa* biofilms. *FEMS Immunol Med Microbiol*. 2010;59(3):292–305.



13. Sawhney R, Berry V. Bacterial biofilm formation, pathogenicity, diagnostics and control: An overview. *Indian J Med Sci.* 2009;63(7): 313–321.
14. Gaynor M, Mankin AS. Macrolide antibiotics: binding site, mechanism of action, resistance. *Curr Top Med Chem.* 2003;3(9):949–961.
15. Canton R, Morosini MI. Emergence and spread of antibiotic resistance following exposure to antibiotics. *FEMS Microbiol Rev.* 2011;35(5): 977–991.
16. Zhang L, Mah TF. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. *J Bacteriol.* 2008;190(13):4447–4452.
17. Cernohorska L, Votava M. Antibiotic synergy against biofilm-forming *Pseudomonas aeruginosa*. *Folia Microbiol (Praha).* 2008;53(1): 57–60.
18. Christensen GD, Simpson WA, Younger JJ, et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. *J Clin Microbiol.* 1985;22(6):996–1006.
19. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard. ninth edition. Villanova, PA: 2012.
20. Schmidtchen A, Wolff H, Hansson C. Differential proteinase expression by *Pseudomonas aeruginosa* derived from chronic leg ulcers. *Acta Derm Venereol.* 2001;81(6):406–409.
21. Okamoto T, Akaike T, Suga M, et al. Activation of human matrix metalloproteinases by various bacterial proteinases. *J Biol Chem.* 1997;272(9):6059–6066.
22. Duan ZG, Yan XJ, He XZ, et al. Extraction and protein component analysis of venom from the dissected venom glands of *Latrodectus tredecimguttatus*. *Comp Biochem Physiol B Biochem Mol Biol.* 2006;145(3–4):350–357.
23. Tsai CM, Frascch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. *Anal Biochem.* 1982; 119(1):115–119.
24. Hoekstra JL, de Neeling AJ, van Klingeren V, Stobberingh EE, van Boven CP. Resistant strains of *Pseudomonas aeruginosa* isolated after exposure to several beta-lactam antibiotics. *Eur J Clin Microbiol.* 1987;6(1):22–27.
25. Cos P, Tote K, Horemans T, Maes L. Biofilms: an extra hurdle for effective antimicrobial therapy. *Curr Pharm Des.* 2010;16(20):2279–2295.
26. Khan W, Bernier SP, Kuchma SL, Hammond JH, Hasan F, O’Toole GA. Aminoglycoside resistance of *Pseudomonas aeruginosa* biofilms modulated by extracellular polysaccharide. *Int Microbiol.* 2010;13(4):207–212.
27. Hoiby N, Bjarsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. *Int J Antimicrob Agents.* 2010;35(4): 322–332.
28. Hoiby N, Ciofu O, Johansen HK, et al. The clinical impact of bacterial biofilms. *Int J Oral Sci.* 2011;3(2):55–65.
29. Simoes M. Antimicrobial strategies effective against infectious bacterial biofilms. *Curr Med Chem.* 2011;18(14):2129–2145.
30. Fluit AC, Schmitz FJ. Bacterial resistance in urinary tract infections: how to stem the tide. *Expert Opin Pharmacother.* 2001;2(5):813–818.
31. Rupp ME, Hamer KE. Effect of subinhibitory concentrations of vancomycin, cefazolin, ofloxacin, L-ofloxacin and D-ofloxacin on adherence to intravascular catheters and biofilm formation by *Staphylococcus epidermidis*. *J Antimicrob Chemother.* 1998;41(2): 155–161.
32. Hatt JK, Rather PN. Role of bacterial biofilms in urinary tract infections. *Curr Top Microbiol Immunol.* 2008;322:163–192.
33. Frei E, Hodgkiss-Harlow K, Rossi PJ, Edmiston CE Jr, Bandyk DF. Microbial pathogenesis of bacterial biofilms: a causative factor of vascular surgical site infection. *Vasc Endovascular Surg.* 2011;45(8):688–696.
34. Fernandez L, Breidenstein EB, Song D, Hancock RE. Role of intracellular proteases in the antibiotic resistance, motility, and biofilm formation of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2012;56(2):1128–1132.
35. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol.* 2011;19(8): 419–426.
36. Anuntagool N, Wuthiekanun V, White NJ, et al. Lipopolysaccharide heterogeneity among *Burkholderia pseudomallei* from different geographic and clinical origins. *Am J Trop Med Hyg.* 2006;74(3): 348–352.
37. Coulon C, Vinogradov E, Filloux A, Sadovskaya I. Chemical analysis of cellular and extracellular carbohydrates of a biofilm-forming strain *Pseudomonas aeruginosa* PA14. *PLoS One.* 2010;5(12):e14220.
38. Sawasdidoln C, Taweechaisupapong S, Sermswan RW, Tattawasart U, Tungpradabkul S, Wongratanacheewin S. Growing *Burkholderia pseudomallei* in biofilm stimulating conditions significantly induces antimicrobial resistance. *PLoS One.* 2010;5(2):e9196.

## Supplementary tables

**Table S1** Minimum inhibitory concentration values of *Staphylococcus aureus* planktonic and biofilm cells

Antibiotics	Planktonic cells	Biofilm cells
Ciprofloxacin	0.5 ± 0.1 µg/mL	128 ± 25 µg/mL
Amoxicillin	4 ± 0.9 µg/mL	512 ± 110 µg/mL
Cotrimoxazole	4 ± 0.0 µg/mL	256 ± 60 µg/mL
Cefaclor	8 ± 1.8 µg/mL	> 1024 µg/mL

**Table S2** Minimum inhibitory concentration values of *Pseudomonas aeruginosa* planktonic and biofilm cells

Antibiotics	Planktonic cells	Biofilm cells
Ciprofloxacin	0.125 ± 0.02 µg/mL	64 ± 13 µg/mL
Ceftazidime	2 ± 0.4 µg/mL	256 ± 80 µg/mL
Cotrimoxazole	256 ± 60 µg/mL	512 ± 100 µg/mL
Amikacin	2 ± 0.0 µg/mL	0.02 ± 0.004 µg/mL

### Infection and Drug Resistance

#### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic

Submit your manuscript here: <http://www.dovepress.com/infection-and-drug-resistance-journal>

resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress